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SUMMARY
Hashimoto’s encephalopathy (HE) is an autoimmune form of encephalopathy, associated with autoimmune thy-
roiditis. Its prevalence is estimated to be 2:100,000. HE is characterized by behavioral changes, mental confu-
sion, dysarthria, ataxia, psychosis, paranoia, convulsions, hallucinations, headache and hyperthermia. Elevated 
thyroid antibodies are necessary for diagnosis and the disease responds dramatically to glucocorticoid therapy.
We describe a patient with HE and panniculitis, an association reported twice in the literature.
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n	 INTRODUCTION
Hashimoto’s encephalopathy (HE) is a non-infectious, autoimmune form of 
encephalopathy, associated with autoim-
mune thyroiditis. Its prevalence is estimat-
ed to be 2:100,000 (1). HE is characterized 
by behavioral changes, mental confusion, 
dysarthria, ataxia, psychosis, paranoia, 
convulsions, hallucinations, headache and 
hyperthermia. Elevated thyroid antibodies 
are necessary for diagnosis. The disease 
responds dramatically to glucocorticoid 
therapy (1-5). 
We describe a patient with HE and pan-
niculitis, an association reported twice in 
the literature: a child with panniculitis, 
vitiligo and thyroid dysfunction (6) and a 
57-year-old woman with panniculitis, pri-
mary biliary cirrhosis (PBC) and Hashi-
moto’s thyroiditis (7).
n	 CASE REPORT
A 70-year old man was admitted to our 
unit for panniculitis, fever (up to 38°C) and 
polyarthralgia. His previous domiciliary 
treatment was beclometasone 2 mg/day for 
3 months.  He was in therapy for thyroid 
dysfunction with L-thyroxine 50 mcg/day. 
TSH value was 5.43 mIU/L, while T4 free 
was 9.37 ng/L. Electrolytes, creatinine, ar-
terial blood gases and pH were in range. 
Glycemic level was 132 mg/dL. His clini-
cal history included recurrent orchitis and 
Hashimoto’s thyroiditis. Anti-thyroglobu-
lin antibodies (805.1 U/mL) and anti-thy-
roid peroxidase (408 U/mL) were elevated. 
Anti-neutrophil cytoplasmic antibodies, 
antinuclear antibodies, and the ACE test 
were negative. Complement fractions lev-
els were in range. Intestinal function was 
regular; there was no abdominal pain or 
other symptoms suggesting inflammatory 
bowel disease and colonoscopy showed no 
endoscopic or histologic alterations. There 
was no lymphadenopathy at chest CT com-
patible with sarcoidosis. During physical 
examination, the patient was awake, orient-
ed and collaborating. He presented  several 
hypodermic nodules in the four limbs. His-
tology of bioptic specimens confirmed sep-
tal panniculitis on the basis of the presence 
of large epidermal septa and sparse inflam-
matory infiltrates involving subcutaneous 
fat with activated lymphocytes in active le-
sions. Older lesions were characterized by 
fibrosis of the widened septa with sparse 
infiltrates of histiocytes, perivascular lym-
phocytes and fibrin deposits. A biopsy of 
the intestinal mucosa was negative. A pos-
itron-emission tomography (PET) showed 
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diffuse uptake of the thyroid gland (SUV 
7.5). Ultrasonography showed multinodu-
lar goiter which was hypervascularized 
at power Doppler. Nothing emerged from 
total-body CT scanning. 
After tapering beclometasone to 0.5 mg/
day in 15 days, the patient presented sud-
den alteration of consciousness, with hy-
perpyrexia up to 39.5°C, headache, psy-
chosis, ataxia, dysphonia, drowsiness and 
mental confusion. Nuchal rigidity or le-
sions at contrast-enhanced CT brain scan 
were absent. C-reactive protein level (3.4 
to 532 mg/L) and leukocytes number (4.32 
to 9.86 x109/L) increased. The electro-
encephalogram demonstrated lazy back-
ground activities. MRI was not performed, 
neither was a lumbar puncture in consid-
eration of the serious deterioration of the 
general condition and state of conscious-
ness of the patient. In the hypothesis of 
HE, treatment with dexamethasone ev 16 
mg was immediately started, in accordance 
with accepted diagnostic criteria (7) (Table 
I). No symptomatic treatment for his psy-
chiatric manifestations was started.  An im-
mediate and permanent improvement was 
seen, with the disappearance of psychotic 
symptoms. Glucocorticoids were tapered 
to 12.5 mg of prednisone/day in 4 weeks, 
with improvement of panniculitis and dis-
appearance of arthralgia. As maintenance 
treatment, prednisone was tapered to 7.5 
mg/die in association with cyclosporin A 
150 mg/die. In the following 24 months, no 
other acute exacerbation occurred and no 
neurologic sequelae remained.
n	 DISCUSSION AND 
CONCLUSIONS
HE is an autoimmune disease that causes 
cerebral vasculitis and directed injury 
against common brain-thyroid antigens. 
This hypothesis is supported by the preva-
lence in female population, by the associa-
tion with other autoimmune diseases and 
by brain biopsy that shows mild lympho-
cytic infiltration of small vessels (8, 9).
Thyroid functionality should be checked 
in those patients with encephalitis of un-
known etiology and HE should be sup-
posed especially in presence of other auto-
immune disease, such as panniculitis, or in 
those patients with thyroid dysfunction and 
neurological signs occurred while tapering 
the corticosteroids.
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Table I - Diagnostic criteria for Hashimoto’s encephalopathy.
Clinical presentations
Encephalopathy with cognitive impairment
Encephalopathy with psychiatric manifestation
Encephalopathy with partial or generalized seizures
Encephalopathy with focal neurological deficits or alteration of consciousness
Laboratory test
Presence of high titer anti-TPO
Exclusion of neurological disease
Exclusion of neurological infection, toxic, and metabolic disorder
Response to treatment
Patient’s neurological status return to baseline level after steroids therapy
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